Panbela Therapeutics, Inc. has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, with the file number 333-276367. The request, dated January 25, 2024, was made under Rule 461 of the Securities Act of 1933, as amended. The company seeks to have the Registration Statement become effective on the same day at 5:30 p.m. Eastern Time, or as soon thereafter as possible. This step is in preparation for a proposed public offering of securities by Panbela Therapeutics. The company has acknowledged its responsibilities under the Act in relation to the offering. Any inquiries regarding this acceleration request have been directed to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, who is serving as counsel for Panbela Therapeutics. The communication was signed by Susan Horvath, the Chief Financial Officer of Panbela Therapeutics.

Panbela Therapeutics, Inc. has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, with the file number 333-276367. The request, dated January 25, 2024, was made under Rule 461 of the Securities Act of 1933, as amended. The company seeks to have the Registration Statement become effective on the same day at 5:30 p.m. Eastern Time, or as soon thereafter as possible. This step is in preparation for a proposed public offering of securities by Panbela Therapeutics. The company has acknowledged its responsibilities under the Act in relation to the offering. Any inquiries regarding this acceleration request have been directed to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, who is serving as counsel for Panbela Therapeutics. The communication was signed by Susan Horvath, the Chief Financial Officer of Panbela Therapeutics.